ArticleWorld journal of surgical oncology2026
A fatty acid metabolism-based deep learning model predicts biochemical recurrence and identifies NUDT19 as a candidate metabolic factor in prostate cancer.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeTo develop a fatty acid metabolism-based deep learning model for predicting biochemical recurrence (BCR) in prostate cancer (PCa) and to identify recurrence-associated metabolic regulators.
methodsTranscriptomic data from TCGA and GEO GSE70769 were integrated to identify fatty acid metabolism-related genes and construct a deep learning model for BCR prediction. Tumor-infiltrating lymphocytes (TILs) were quantified from H&E-stained slides using a convolutional neural network-based approach. Single-cell RNA sequencing data were analyzed to identify candidate metabolic regulators enriched in malignant epithelial cells. Immunohistochemistry was performed to examine the protein expression patterns of NUDT19 and its expression associations with key fatty acid metabolism enzymes, including FASN, ACACA, and CPT1A. Functional roles were further evaluated using in vitro assays, xenograft models, and serum metabolomics.
resultsThe model effectively stratified PCa patients into high- and low-risk groups with distinct BCR-free survival outcomes. The high-risk group showed increased TIL infiltration, suggesting a more immune-infiltrated or inflammatory tumor microenvironment. Integrated single-cell and bulk transcriptomic analyses identified NUDT19 as a candidate metabolic regulator predominantly expressed in malignant epithelial cells and positively correlated with FASN, ACACA, and CPT1A. NUDT19 knockdown suppressed PCa cell proliferation, migration, and invasion, induced apoptosis, and inhibited tumor growth in vivo. Serum metabolomics further revealed that differential metabolites were enriched in fatty acid metabolism-related pathways.
conclusionsThis study establishes a fatty acid metabolism-based deep learning model for BCR prediction and identifies NUDT19 as a candidate metabolic regulator associated with lipid metabolic remodeling and PCa progression. These findings suggest a metabolically active, inflammation-associated recurrence subtype and support further investigation of NUDT19 as a potential therapeutic target in PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.